Adaptive T cell immunotherapy in cancer.

Ti, Dongdong; Bai, Miaomiao; Li, Xiaolei; Wei, Jianshu; Chen, Deyun; Wu, Zhiqiang; Wang, Yao; Han, Weidong

Ti, Dongdong; Bai, Miaomiao; Li, Xiaolei; Wei, Jianshu; Chen, Deyun; Wu, Zhiqiang; Wang, Yao; Han, Weidong.

Afiliação

Ti D; Bio-therapeutic Department, Chinese PLA General Hospital, Beijing, 100853, China.
Bai M; Bio-therapeutic Department, Chinese PLA General Hospital, Beijing, 100853, China.
Li X; Bio-therapeutic Department, Chinese PLA General Hospital, Beijing, 100853, China.
Wei J; Bio-therapeutic Department, Chinese PLA General Hospital, Beijing, 100853, China.
Chen D; Bio-therapeutic Department, Chinese PLA General Hospital, Beijing, 100853, China.
Wu Z; Bio-therapeutic Department, Chinese PLA General Hospital, Beijing, 100853, China. wuzhiqiang1006@163.com.
Wang Y; Bio-therapeutic Department, Chinese PLA General Hospital, Beijing, 100853, China. wangyao_301@hotmail.com.
Han W; Bio-therapeutic Department, Chinese PLA General Hospital, Beijing, 100853, China. hanwdrsw69@yahoo.com.

Sci China Life Sci ; 64(3): 363-371, 2021 Mar.

Article em En | MEDLINE | ID: mdl-32712831

Assuntos

Imunoterapia Adotiva/métodos; Linfócitos do Interstício Tumoral/imunologia; Neoplasias/terapia; Receptores de Antígenos Quiméricos/imunologia; Subpopulações de Linfócitos T/imunologia; Humanos

Palavras-chave

T cell receptor; adoptive T cell therapy; chimeric antigen receptor; tumor-infiltrating lymphocytes

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoterapia Adotiva / Subpopulações de Linfócitos T / Linfócitos do Interstício Tumoral / Receptores de Antígenos Quiméricos / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google